| Coagulation assays
VWF:Ac was measured using the INNOVANCE VWF Ac reagent (Siemens Healthcare Diagnostics, Marburg, Germany) according to a previously described method. 18 
| Preparation of IRP
IRP was prepared from 10 healthy volunteer plasma samples. Blood specimens were collected into 3.2% sodium citrate tubes (BD Vacutainer, BD Diagnostics, Plymouth, UK), centrifuged at 1500 g for 10 minutes at room temperature to generate platelet-free plasma, pooled, aliquoted into Eppendorf type tubes (composed of a nonactivating plastic), and frozen at −70°C. Prior to testing, samples were thawed in a 37°C water bath (for approximately 5 minutes) and mixed thoroughly. The volunteers were healthy laboratory employees without history of hemorrhagic episodes, who were not taking any medication for at least 10 days before blood collection, had a normal coagulation screen profile and normal VWF screening assays results, and who provided written consent. Exclusion criteria consisted of a positive personal and/or family bleeding history, inflammation, pregnancy, and oral contraceptive use.
| VWF multimer method developed by Sebia
All constituents of the assay (reagents, instruments, and software) were provided by Sebia (Lisses, France). Plasma samples were treated with sample diluent (pH 5.0 ± 0.5) and were pre-incubated for 20 minutes at 45°C. The dilution ratio was adapted based on the VWF:Ag result according to the manufacturer's instructions. The treated plasma samples were grouped into quintuplets, loaded onto Hydragel 5 von Willebrand multimer gels, and then subjected to a migration step using a Hydrasys 2 system with the following parameters: under 1 W constant, 10°C, controlled by the Peltier effect, until 170 Vh has accumulated, and a duration of approximately 115 minutes. The multimers were fixed on the gel using rabbit origin anti-VWF antibodies and then were probed with a secondstep immunofixation by horseradish peroxidase (HRP)-conjugated antimammalian IgG. VWF multimers were evaluated by visualization after coloring the gels with commercially available reagents (commercial abbreviation TTF1/TTF2), and densitometric gel scan/graphical curves were produced and visualized with Sebia Phoresis CORE software. 
| Previous studies confirming the VWD diagnosis

| VWF multimers in patient samples
VWF multimer electrophoresis interpretations of 9 VWD type (1, were completely normal. In all 7 surveys, VWF multimer electrophoresis interpretation and final interpretation of the VWD type were in agreement with expert opinion (Table 2 ).
| VWF multimers in EQA samples
| D ISCUSS I ON
VWF multimers should not be used as a standalone test to diagnose VWD. 21 The critical clinical utility of VWF multimers is in differenti- 14, 17, 23 In addition, a certain proportion of interpretative errors arise due to test panels lacking the VWF multimer assay.
5,16
The main methods in clinical use for the visualization of VWF multimers remain in-house-developed electrophoresis methods with typical overnight electrophoretic runs in agarose gels (alternatively, nitrocellulose or polyvinylidene difluoride) at concentrations ranging from 1% to 3% 14, 21, 23 with different options for immunologically detected multimer visualization (either radioactive, colorimetric, luminographic, or fluorometric methods). 23 Radioactive techniques are potentially hazardous, but conventional nonradioactive methods lack sensitivity and optimal resolution power, 13 potentially leading clinicians to misclassification of the VWD subtype. 20 Luminographic methods are much safer and are reported to allow visualization of multimers with confidence and high sensitivity. is not an urgent analysis.
Another disadvantage that many in-house electrophoresis methods possess is their inability to carry out quantitative analysis of VWF multimers. 13, 20 Quantitative results can provide objective measures of the VWF structure to better define subtle changes in the VWD subtypes, such as dominant VWD type 1/2E (IIE) due to mutations in the D3 domain with aberrant triplet structure or the lack of outer bands or pronounced inner bands together with a relative decrease in LMW multimers. 24, 25 However, the current classification for VWD does not consider the quantity of loss of the HMW multimers. 20 The Sebia method provides quantitative VWF multimer results and allows, if desired, splitting curves into multimer subsets.
Laboratories may be able to establish normal ranges for different multimer sizes (LMW, IMW, and HMW) and quantify the percentage of loss in abnormal samples. The quantitative performance of the Sebia VWF multimer assay (reference ranges, clinical decision limits) should be assessed in future studies. Unfortunately, the Sebia method does not allow the visualization of VWF multimer triplets.
Therefore, the main difference of it, compared with noncommercial assays, is the "quantification" itself, although this can be equally ad- showing substantial error rates ranging from 10% to 52%. 17 The
North American Specialized Coagulation Laboratory Association (NASCOLA) showed an overall 14.7% (7-22%) erroneous sur- 
